Tag: CAR-T
CIRM Grants $3.99 Million to Poseida’s P-PSMA101 CAR-T for Prostate Cancer
Poseida Therapeutics Inc., headquartered in San Diego, spun-out of Transposagen Biopharmaceuticals in 2015. The company is translating best-in-class gene engineering technologies into lifesaving cell therapies. This includes developing CAR T-cell immunotherapies for multiple myeloma (phase I), prostate and other...
Cesca Therapeutics’ CTO Talks CAR-T Manufacturing
Cesca Therapeutics Inc. is in the business of developing, commercializing and marketing a range of automated technologies for CAR-T and other cell-based therapies. The device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care...
Cesca Therapeutics Inc. Has Released The X-Mini™ Cell Selection Kit For The CAR-T Research...
Two CAR-T cell therapies have been approved by the USA Food and Drug Administration (FDA) within the past year for blood cancers. Cellular therapies have been approved in the past such as Provenge for prostate cancer, the IP of...
